Companies formed

Since 1997, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and has spun out a new company every two months on average.

Over £266 million in external investment has been raised by Oxford University Innovation spinouts since 2000, and five are currently listed on London’s AIM market.

The creation of these new spinout companies also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.

2006

TdeltaS is committed to developing science-based proprietary products that sit at the interface of food and pharmaceuticals - nutraceuticals - and offer real improvement in human physical and mental performance.

Incorporated in March 2006

Origin: Oxford University, Department of Physiology, Anatomy and Genetics

Contact: James Mallinson

2005

Velocys, previously Oxford Catalysts, produces speciality catalysts for the generation of clean fuels, from both conventional fossil fuels and renewable sources such as biomass.

Incorporated in December 2005

Origin: Oxford University, Department of Inorganic Chemistry

Contact: James Mallinson

Celleron is an oncology healthcare company that has developed biomarkers using epigenetic techniques that match drugs to responsive disease.

Incorporated in November 2005

Origin: Oxford University, Department of Pharmacology

Contact: James Mallinson

Robust, networked sensors for oilfield machinery, drilling and metering.

Incorporated in June 2005

Origin: Oxford University, Department of Organic Chemistry

Contact: James Mallinson

Oxford Nanopore Technologies is developing and commercialising a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins.

Incorporated in May 2005

Origin: Oxford University, Department of Chemistry

Contact: James Mallinson

2004

EKB Technology commercialises a revolutionary Bioprocessing Technology developed for the use of biological systems such as plant and animal cells and microorganisms to modify, produce or purify chemical intermediates.

Incorporated in December 2004

Origin: Oxford University, Department of Earth Sciences

Contact: James Mallinson

Surface Therapeutics is a drug discovery and development company developing innovative new drugs to treat inflammatory epithelial diseases of the skin and lungs. Surface Therapeutics was acquired by Serentis Inc in September 2007.

Incorporated in November 2004

Origin: Oxford University, Wellcome Trust Centre for Human Genetics

Contact: James Mallinson

G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.

Incorporated in June 2004

Origin: Oxford University, Department of Pharmacology

Contact: James Mallinson

Oxford Medical Diagnostics develops and supplies breath analysis technologies for rapid, accurate, and low-cost monitoring of diseases and metabolic functions.

Incorporated in June 2004

Origin: Oxford University, Department of Physical and Theoretical Chemistry

Contact: James Mallinson

2003

Oxford Consultants for Social Inclusion (OCSI) helps local government identify deprived neighbourhoods, target resources, evaluate programme effectiveness and strengthen regeneration bids.

Incorporated in August 2003

Origin: Oxford University, Department of Social Policy and Intervention

Contact: James Mallinson

A biotherapeutics company, established to exploit the work in Viral Hepatitis undertaken at Imperial College, London and at Oxford University through the Wellcome Trust Centre for Human Genetics.

Incorporated in July 2003

Origin: Oxford University, Wellcome Trust Centre for Human Genetics

Contact: James Mallinson

ReOx is a drug discovery company that is building on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).

Incorporated in May 2003

Origin: Oxford University, Centre for Cellular and Molecular Physiology

Contact: James Mallinson

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Incorporated in February 2003

Origin: Oxford University, Department of Organic Chemistry

Contact: James Mallinson

2002

BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.

Incorporated in November 2002

Origin: Oxford University, Department of Pathology

Contact: James Mallinson

Oxford Risk is the market-leading provider of customer risk profilers. Their products reveal the level of risk customers are willing and able to take with their financial investments.

Incorporated in November 2002

Origin: Oxford University, Nuffield Department of Population Health

Contact: James Mallinson

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology.

Incorporated in October 2002

Origin: Oxford University, Nuffield Department of Clinical Medicine

Contact: James Mallinson

Search

Ready to get in touch?

Contact Us
Search
© Oxford University Innovation